(Reuters) – Drugmaker Indivior said on Monday it will pay $385 million to settle a lawsuit brought by direct purchasers on claims it illegally suppressed generic competition for its opioid addiction treatment Suboxone.
Indivior had in June agreed to pay $102.5 million to settle a lawsuit by dozens of U.S. states regarding the claims.
The agreement with the direct purchasers will mark the end of the multi-district litigation relating to Suboxone, it said.
Indivior said it will take a charge of $228 million in the third quarter, above the current remaining provision of $157 million, which will be excluded from adjusted earnings.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Janane Venkatraman and Varun H K)
